---
layout: default
title: Buprenorphine
description: "Buprenorphine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 6 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 36
evidence_level: L5
indication_count: 6
---

# Buprenorphine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>6</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Buprenorphineï¼šå¾ç–¼ç—›æ§åˆ¶åˆ°æ€¥æ€§é–“æ­‡æ€§ç´«è³ªç—‡

## ä¸€å¥è©±ç¸½çµ
<p class="key-answer" data-question="Buprenorphine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Buprenorphine åŸç‚ºé¡é´‰ç‰‡éƒ¨åˆ†è‡´æ•ˆåŠ‘ï¼Œç”¨æ–¼ä¸­é‡åº¦ç–¼ç—›åŠé´‰ç‰‡é¡æˆç™®æ›¿ä»£ç™‚æ³•ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°æ€¥æ€§é–“æ­‡æ€§ç´«è³ªç—‡(acute intermittent porphyria)æœ‰æ²»ç™‚æ½›åŠ›ã€‚
</p>

## å¿«é€Ÿç¸½è¦½
| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ä¸­é‡åº¦ç–¼ç—›ã€é´‰ç‰‡é¡ç‰©è³ªæˆç™®æ›¿ä»£ç™‚æ³• |
| é æ¸¬æ–°é©æ‡‰ç—‡ | opiate dependenceã€morphine dependenceã€acute intermittent porphyriaã€lingual-facial-buccal dyskinesiaã€chronic tic disorderã€continuous spikes and waves during sleep |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.41% |
| è­‰æ“šç­‰ç´š | L4 (å€‹æ¡ˆå ±å‘Š/éº»é†‰ç®¡ç†ç¶“é©—) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Consider |

## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. acute intermittent porphyria</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.41%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Buprenorphine æ˜¯ä¸€ç¨®ç¨ç‰¹çš„é¡é´‰ç‰‡è—¥ç‰©ï¼š

1. **éƒ¨åˆ†muå—é«”è‡´æ•ˆåŠ‘**ï¼šæä¾›æ­¢ç—›æ•ˆæœä½†å‘¼å¸æŠ‘åˆ¶é¢¨éšªè¼ƒä½
2. **kappaå—é«”æ‹®æŠ—åŠ‘**ï¼šå¯èƒ½æ¸›å°‘ç„¦æ…®å’Œç…©èº
3. **ç´«è³ªç—‡å®‰å…¨æ€§**ï¼šç›¸è¼ƒæ–¼å…¶ä»–é¡é´‰ç‰‡è—¥ç‰©ï¼Œè¢«èªç‚ºåœ¨ç´«è³ªç—‡æ‚£è€…ä¸­è¼ƒç‚ºå®‰å…¨
4. **éº»é†‰ç®¡ç†ç¶“é©—**ï¼šå·²æœ‰æ–‡ç»å ±å‘Š buprenorphine æˆåŠŸç”¨æ–¼ç´«è³ªç—‡æ‚£è€…çš„è¡“ä¸­åŠè¡“å¾Œæ­¢ç—›

æ€¥æ€§é–“æ­‡æ€§ç´«è³ªç—‡(AIP)æ‚£è€…å¸¸å› ç–¼ç—›ç™¼ä½œéœ€è¦æ­¢ç—›è—¥ï¼Œä½†è¨±å¤šè—¥ç‰©æœƒèª˜ç™¼æˆ–åŠ é‡ç™¼ä½œã€‚Buprenorphine å¯èƒ½æ˜¯é€™é¡æ‚£è€…è¼ƒå®‰å…¨çš„æ­¢ç—›é¸æ“‡ã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡é‡å° buprenorphine æ²»ç™‚æ€¥æ€§é–“æ­‡æ€§ç´«è³ªç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

PubMed æª¢ç´¢ç™¼ç¾1ç¯‡ç›´æ¥ç›¸é—œçš„å€‹æ¡ˆå ±å‘Šï¼š

**Ii C ç­‰äºº (1993)** - *éº»é†‰é›œèªŒ (Masui)*
- å ±å‘Šä¸€ä¾‹ç–‘ä¼¼æ€¥æ€§é–“æ­‡æ€§ç´«è³ªç—‡æ‚£è€…çš„éº»é†‰ç®¡ç†
- è¡“å¾Œä½¿ç”¨ buprenorphine é€²è¡Œç–¼ç—›æ§åˆ¶
- æ‚£è€…æœªå‡ºç¾ç´«è³ªç—‡æ€¥æ€§ç™¼ä½œ
- æ”¯æŒ buprenorphine åœ¨ AIP æ‚£è€…ä¸­çš„å®‰å…¨ä½¿ç”¨

å…¶ä»–ç›¸é—œæ–‡ç»æ¶‰åŠ buprenorphine åœ¨å¤±æ™ºç—‡æ‚£è€…æ¿€å‹•è¡Œç‚ºçš„ç–¼ç—›ç®¡ç†ï¼š
- Husebo BS ç­‰äººå¤šç¯‡ç ”ç©¶(2011-2014)æ¢è¨é¡é´‰ç‰‡è—¥ç‰©åœ¨å¤±æ™ºç—‡ç›¸é—œç–¼ç—›ç®¡ç†ä¸­çš„æ‡‰ç”¨

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. lingual-facial-buccal dyskinesia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.32%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.32%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. chronic tic disorder</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.13%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.13%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. continuous spikes and waves during sleep</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.05%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.05%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. benign shuddering attacks</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.03%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.03%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. extrapyramidal and movement disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.03%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.03%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

## å°ç£ä¸Šå¸‚è³‡è¨Š
Buprenorphine åœ¨å°ç£æœ‰å¤šç¨®åŠ‘å‹ï¼š

**èˆŒä¸‹éŒ /å«èˆŒä¸‹è¤‡æ–¹éŒ **
- è§£ä½³ç›ŠèˆŒä¸‹éŒ  - ç”¨æ–¼é´‰ç‰‡é¡ç‰©è³ªæˆç™®æ›¿ä»£ç™‚æ³•
- é€Ÿå¿…æ²»èˆŒä¸‹éŒ  (å« naloxone) - æˆç™®æ›¿ä»£ç™‚æ³•

**ç¶“çš®è²¼ç‰‡**
- èˆ’å…ç–¼è²¼ç‰‡ - ç”¨æ–¼ä¸­åº¦éç™Œç—‡ç–¼ç—›
- å¤šç¨®åŠ‘é‡è¦æ ¼ (5, 10, 20 mcg/hr)

**æ³¨å°„åŠ‘**
- ç”¨æ–¼è¡“å¾ŒåŠä¸­é‡åº¦ç–¼ç—›

æ ¸å‡†é©æ‡‰ç—‡ï¼š
- ä¸­é‡åº¦ç–¼ç—›ç®¡ç†
- é´‰ç‰‡é¡ç‰©è³ªæˆç™®æ›¿ä»£ç™‚æ³•

## å®‰å…¨æ€§è€ƒé‡
### ç´«è³ªç—‡ç›¸é—œè€ƒé‡
- è¢«åˆ—ç‚ºç´«è³ªç—‡æ‚£è€…ã€Œå¯èƒ½å®‰å…¨ã€çš„é¡é´‰ç‰‡è—¥ç‰©
- ä½†ä»æ‡‰è¬¹æ…ä½¿ç”¨ï¼Œå¯†åˆ‡ç›£æ¸¬
- é¿å…èˆ‡å·²çŸ¥æœƒèª˜ç™¼ç´«è³ªç—‡çš„è—¥ç‰©ä½µç”¨

### ä¸€èˆ¬å‰¯ä½œç”¨
- å™å¿ƒã€å˜”å
- ä¾¿ç§˜
- é ­æšˆã€å—œç¡
- å‡ºæ±—

### åš´é‡è­¦èª
- å‘¼å¸æŠ‘åˆ¶é¢¨éšª(è¼ƒå®Œå…¨è‡´æ•ˆåŠ‘ä½)
- æˆç™®æ½›åŠ›
- è‚åŠŸèƒ½ä¸å…¨è€…éœ€èª¿æ•´åŠ‘é‡

### è—¥ç‰©äº¤äº’ä½œç”¨(ä¸»è¦)
| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ |
|-------------|---------|
| Ethanol (é…’ç²¾) | é‡åº¦ |
| Methylene blue | é‡åº¦ |
| Codeine | é‡åº¦ |
| è‹¯äºŒæ°®å¹³é¡ | ä¸­åº¦-é‡åº¦ |

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šConcomitant use of buprenorphine with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics...
- å»ºè­°ï¼šThe use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the ...

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**å¡ç“¦** ğŸ”´ Major
- å½±éŸ¿ï¼šåš´é‡ä¸­æ¨ç¥ç¶“æŠ‘åˆ¶é¢¨éšª
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Adrenal Insufficiency** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šPatients with Addison's disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (op...

**Gallbladder Diseases** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šNarcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, espe...

**ç”²ç‹€è…ºæ©Ÿèƒ½ä½ä¸‹** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šPatients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioi...

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šAlthough narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and the...

**ç™²ç™‡** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šç™²ç™‡ç™¼ä½œã€‚

**å°¿æ»¯ç•™** ğŸŸ¡ Moderate
- ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šè€å¹´äººã€‚

**Gastrointestinal Diseases** ğŸŸ¢ Minor
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Dysentery** ğŸŸ¢ Minor
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- æ³¨æ„äº‹é …ï¼šNarcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e...

**Premature Birth** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**Intestinal Obstruction** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**Myocardial Infarction** ğŸŸ¢ Minor
- æ³¨æ„äº‹é …ï¼šOpiate partial agonists may increase systemic and pulmonary arterial pressure and systemic vascular resistance, particularly when given by intravenous...

**Substance-Related Disorders** ğŸŸ¢ Minor
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Intracranial Hypertension** ğŸŸ¢ Minor
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Respiratory Insufficiency** ğŸŸ¢ Minor
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥
**è­‰æ“šç­‰ç´š**ï¼šL4 (å€‹æ¡ˆå ±å‘Šå±¤ç´šè­‰æ“š)

**å»ºè­°**ï¼š
1. å°æ–¼ AIP æ‚£è€…éœ€è¦æ­¢ç—›è—¥æ™‚ï¼Œbuprenorphine å¯ä½œç‚ºè€ƒæ…®é¸é …
2. æ‡‰åœ¨è¡€æ¶²ç§‘åŠç–¼ç—›å°ˆç§‘é†«å¸«å…±åŒè©•ä¼°ä¸‹ä½¿ç”¨
3. å»ºè­°å¾ä½åŠ‘é‡é–‹å§‹ï¼Œå¯†åˆ‡ç›£æ¸¬ç´«è³ªç—‡ç—‡ç‹€
4. é¿å…èˆ‡å…¶ä»– CYP450 èª˜å°åŠ‘æˆ–ç´«è³ªç—‡èª˜ç™¼è—¥ç‰©ä½µç”¨

**ä¸‹ä¸€æ­¥ç ”ç©¶æ–¹å‘**ï¼š
- ç³»çµ±æ€§æ”¶é›† AIP æ‚£è€…ä½¿ç”¨ buprenorphine çš„å®‰å…¨æ€§æ•¸æ“š
- å»ºç«‹ç´«è³ªç—‡æ‚£è€…é¡é´‰ç‰‡è—¥ç‰©ä½¿ç”¨æŒ‡å¼•
- æ¯”è¼ƒä¸åŒé¡é´‰ç‰‡è—¥ç‰©åœ¨ç´«è³ªç—‡æ‚£è€…ä¸­çš„å®‰å…¨æ€§ç‰¹æ€§

**ç‰¹åˆ¥æ³¨æ„**ï¼šæ­¤ç‚ºæ¢ç´¢æ€§å»ºè­°ï¼Œè‡¨åºŠä½¿ç”¨ä»éœ€ä¾æ“šå€‹æ¡ˆè©•ä¼°åŠå°ˆç§‘é†«å¸«åˆ¤æ–·ã€‚

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Felodipine]({{ "/drugs/felodipine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Methionine]({{ "/drugs/methionine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Urea]({{ "/drugs/urea/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Fenoterol]({{ "/drugs/fenoterol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Avelumab]({{ "/drugs/avelumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Buprenorphineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/buprenorphine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_buprenorphine,
  title = {Buprenorphineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/buprenorphine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
